Izixate

Methotrexate, the active ingredient in Izixate, is an antimetabolite (folate antagonist) presented as an injectable solution for intravenous or subcutaneous use. It is used to treat autoimmune diseases and certain cancers in adult patients.

GNH USA supplies Izixate as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Izixate (methotrexate) acts on the folate pathway and is employed in several disease categories.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and improves plaque lesions. - Acute lymphoblastic leukemia: interferes with malignant cell replication to achieve remission. - Non‑Hodgkin lymphoma: inhibits tumor growth as part of combination chemotherapy. - Ectopic pregnancy: terminates trophoblastic tissue to avoid surgical intervention.

Methotrexate may cause a range of adverse reactions.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Oral mucosal ulceration. - Elevated liver enzymes. - Mild decrease in blood cell counts.

Serious or Rare Side Effects: - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infections due to bone‑marrow suppression. - Renal failure from crystal nephropathy. - Pancytopenia leading to severe anemia, leukopenia or thrombocytopenia.

Patients receiving Izixate require careful monitoring and specific precautions.

- Monitor liver function: perform regular hepatic enzyme tests. - Monitor blood counts: check complete blood count before each dose. - Avoid use in pregnancy: methotrexate is teratogenic and contraindicated. - Adjust dose in renal impairment: assess renal function and modify accordingly. - Counsel on infection risk: advise patients to report signs of infection promptly. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Azathioprine: additive bone‑marrow suppression. - Allopurinol: may increase methotrexate plasma levels. - Warfarin: enhanced anticoagulant effect, monitor INR. - Oral contraceptives: reduced efficacy, consider alternative contraception.